Home Health News AstraZeneca coronavirus vaccine heads to late-stage study – MarketWatch

AstraZeneca coronavirus vaccine heads to late-stage study – MarketWatch

1 min read
0
0
69

[ad_1]

AstraZeneca PLC
AZN,
+0.55%

said late Monday its COVID-19 vaccine candidate advanced into late-stage U.S. clinical trials to gauge its effectiveness.

AstraZeneca said the Phase III trial is seeking up to 30,000 participants to test the vaccine, designated as AZD1222. Participants will either receive two doses of AZD1222 or a saline placebo four weeks apart.

In July, AstraZeneca said an early-to-mid-stage study showed the vaccine was “well tolerated and generated robust immune responses” against SARS-CoV-2, the virus that causes COVID-19.

U.S.-traded shares of AstraZeneca rose 0.2% after hours, following a 0.6% rise to close the regular session at $56.00.

Let’s block ads! (Why?)

[ad_2]
Source link

Load More Related Articles
Load More By admin
Load More In Health News

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also

UK coronavirus variant cases doubling every 10 days in US, study finds – Fox News

[ad_1] The highly-contagious COVID-19 variant first detected in the United Kingdom is now …